Production (Stage)
Galera Therapeutics, Inc.
GRTX
$0.0326
$0.005118.55%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.46% | -14.70% | -31.14% | -69.94% | -53.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.11% | -68.64% | -66.23% | -74.96% | -67.03% |
| Operating Income | 57.11% | 68.64% | 66.23% | 74.96% | 67.03% |
| Income Before Tax | 63.66% | 11.74% | 61.63% | 80.38% | 75.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.66% | 11.74% | 62.97% | 80.38% | 75.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.66% | 11.74% | 62.97% | 80.38% | 75.26% |
| EBIT | 57.11% | 68.64% | 66.23% | 74.96% | 67.03% |
| EBITDA | 57.14% | 67.28% | 66.24% | 74.97% | 67.04% |
| EPS Basic | 79.88% | 13.24% | 69.04% | 84.52% | 84.00% |
| Normalized Basic EPS | 79.92% | 80.84% | 76.28% | 84.52% | 84.01% |
| EPS Diluted | 79.88% | 13.24% | 69.04% | 84.52% | 84.00% |
| Normalized Diluted EPS | 79.92% | 80.84% | 76.28% | 84.52% | 84.01% |
| Average Basic Shares Outstanding | 81.10% | 1.79% | 19.60% | 26.74% | 54.54% |
| Average Diluted Shares Outstanding | 81.10% | 1.79% | 19.60% | 26.74% | 54.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |